1 Dion, L. et al. The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer. J Clin Med9, doi:10.3390/jcm9072239 (2020).
2 Davis, A., Tinker, A. V. & Friedlander, M. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol133, 624-631, doi:10.1016/j.ygyno.2014.02.038 (2014).
3 Freimund, A. E., Beach, J. A., Christie, E. L. & Bowtell, D. D. L. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. Hematol Oncol Clin North Am32, 983-996, doi:10.1016/j.hoc.2018.07.007 (2018).
4 Lloyd, K. L., Cree, I. A. & Savage, R. S. Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer15, 117, doi:10.1186/s12885-015-1101-8 (2015).
5 Kalow, W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J6, 162-165, doi:10.1038/sj.tpj.6500361 (2006).
6 Binju, M. et al. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. Biochim Biophys Acta Gen Subj1863, 371-378, doi:10.1016/j.bbagen.2018.11.005 (2019).
7 Spentzos, D. et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol23, 7911-7918, doi:10.1200/JCO.2005.02.9363 (2005).
8 Bernardini, M. et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia7, 603-613, doi:10.1593/neo.04760 (2005).
9 Chen, Y., Bi, F., An, Y. & Yang, Q. Coexpression network analysis identified Kruppel-like factor 6 (KLF6) association with chemosensitivity in ovarian cancer. J Cell Biochem, doi:10.1002/jcb.27567 (2018).
10 Zhang, L., Zhang, X., Fan, S. & Zhang, Z. Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis. Medicine (Baltimore)98, e17803, doi:10.1097/MD.0000000000017803 (2019).
11 Bagnoli, M. et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol17, 1137-1146, doi:10.1016/S1470-2045(16)30108-5 (2016).
12 Benvenuto, G. et al. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. Int J Cancer147, 565-574, doi:10.1002/ijc.32935 (2020).
13 Choi, J. et al. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer. BMC Cancer20, 413, doi:10.1186/s12885-020-06922-1 (2020).
14 Zhang, W. et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol16, 133, doi:10.1186/s13059-015-0694-1 (2015).
15 Hafner, M. et al. Barcoded cDNA library preparation for small RNA profiling by next-generation sequencing. Methods58, 164-170, doi:10.1016/j.ymeth.2012.07.030 (2012).
16 Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature474, 609-615, doi:10.1038/nature10166 (2011).
17 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol15, 550, doi:10.1186/s13059-014-0550-8 (2014).
18 Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics9, 559, doi:10.1186/1471-2105-9-559 (2008).
19 Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics28, 1353-1358, doi:10.1093/bioinformatics/bts163 (2012).
20 Chang, L., Zhou, G., Soufan, O. & Xia, J. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res48, W244-W251, doi:10.1093/nar/gkaa467 (2020).
21 Andres-Leon, E., Gomez-Lopez, G. & Pisano, D. G. Prediction of miRNA-mRNA Interactions Using miRGate. Methods Mol Biol1580, 225-237, doi:10.1007/978-1-4939-6866-4_15 (2017).
22 Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res14, 5198-5208, doi:10.1158/1078-0432.CCR-08-0196 (2008).
23 Bagnoli, M. et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget2, 1265-1278, doi:10.18632/oncotarget.401 (2011).
24 Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer19, 197-208, doi:10.1530/ERC-11-0329 (2012).
25 Aguirre-Gamboa, R. et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One8, e74250, doi:10.1371/journal.pone.0074250 (2013).
26 Kim, H., Bhattacharya, A. & Qi, L. Endoplasmic reticulum quality control in cancer: Friend or foe. Semin Cancer Biol33, 25-33, doi:10.1016/j.semcancer.2015.02.003 (2015).
27 Tian, J., Liu, R. & Qu, Q. Role of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma. Oncol Lett13, 1437-1443, doi:10.3892/ol.2017.5580 (2017).
28 Bastola, P., Neums, L., Schoenen, F. J. & Chien, J. VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal. Mol Oncol10, 1559-1574, doi:10.1016/j.molonc.2016.09.005 (2016).
29 Koundouros, N. & Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer122, 4-22, doi:10.1038/s41416-019-0650-z (2020).
30 Nie, L. Y. et al. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep30, 1346-1354, doi:10.3892/or.2013.2575 (2013).
31 Porstmann, T. et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene24, 6465-6481, doi:10.1038/sj.onc.1208802 (2005).
32 Wang, H. Q. et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene24, 3574-3582, doi:10.1038/sj.onc.1208463 (2005).
33 Wheeler, L. J. et al. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. iScience19, 474-491, doi:10.1016/j.isci.2019.07.049 (2019).
34 Pinto, B. A. S., Franca, L. M., Laurindo, F. R. M. & Paes, A. M. A. Unfolded Protein Response: Cause or Consequence of Lipid and Lipoprotein Metabolism Disturbances? Adv Exp Med Biol1127, 67-82, doi:10.1007/978-3-030-11488-6_5 (2019).
35 Hao, D. et al. Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity. Clin Cancer Res24, 3560-3571, doi:10.1158/1078-0432.CCR-17-3862 (2018).
36 Mahadevan, N. R. et al. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc Natl Acad Sci U S A108, 6561-6566, doi:10.1073/pnas.1008942108 (2011).
37 Cubillos-Ruiz, J. R. et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell161, 1527-1538, doi:10.1016/j.cell.2015.05.025 (2015).
38 Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med16, 880-886, doi:10.1038/nm.2172 (2010).
39 Wagschal, A. et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med21, 1290-1297, doi:10.1038/nm.3980 (2015).
40 Adlakha, Y. K. et al. Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRalpha expression and cholesterol homeostasis. Cell Death Dis4, e780, doi:10.1038/cddis.2013.301 (2013).
41 Hedditch, E. L. et al. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst106, doi:10.1093/jnci/dju149 (2014).
42 Zheng, L., Li, L., Lu, Y., Jiang, F. & Yang, X. A. SREBP2 contributes to cisplatin resistance in ovarian cancer cells. Exp Biol Med (Maywood)243, 655-662, doi:10.1177/1535370218760283 (2018).
43 Li, B., Chen, H., Wu, N., Zhang, W. J. & Shang, L. X. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer24, 1381-1388, doi:10.1097/IGC.0000000000000252 (2014).
44 Amini-Farsani, Z., Sangtarash, M. H., Shamsara, M. & Teimori, H. MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway. Cytotechnology70, 203-213, doi:10.1007/s10616-017-0134-z (2018).
45 Li, J. et al. Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer. Int J Oncol, doi:10.3892/ijo.2017.3898 (2017).
46 Sun, C. et al. miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27(kip1.). Oncol Lett6, 507-512, doi:10.3892/ol.2013.1393 (2013).
47 Dai, R. et al. miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)- and MEK/ERK-mediated cell cycle regulation. Biol Chem391, 791-801, doi:10.1515/BC.2010.072 (2010).
48 Zhang, Y. et al. Association of serum lipids and severity of epithelial ovarian cancer: an observational cohort study of 349 Chinese patients. J Biomed Res32, 336-342, doi:10.7555/JBR.32.20170096 (2018).
49 Li, A. J., Elmore, R. G., Chen, I. Y. & Karlan, B. Y. Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. Gynecol Oncol116, 78-81, doi:10.1016/j.ygyno.2009.09.027 (2010).
50 Topouza, D. G. et al. Novel regulatory and transcriptional networks associated with resistance to platinum-based chemotherapy in ovarian cancer. bioRxiv, doi:https://doi.org/10.1101/2020.09.09.289868 (2021).